MKI-2
MKI-2 is a selective MASTL inhibitor with an IC50 of 37.44 nM. MKI-2 induces mitotic catastrophe resulting from the modulation of the MASTL-PP2A axis in breast cancer cells. MKI-2 reduces phospho-ENSA, total, phospho-c-Myc levels. MKI-2 inhibts cancer cells proliferation, migration and induces DNA damage. MKI-2 inhibits germinal vesicle breakdown in mouse oocytes. MKI-2 can be used for the research of cancer, such as breast cancer.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 438204-56-9
- Formel: C22H19N7
- Molecular Weight:381.43
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Alle DNA/RNA Synthesis Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Beschreibung
In Vitro
MKI-2 potently inhibits recombinant MASTL kinase activity with an IC50 of 37.44 nM[1].
MKI-2 (14 h) inhibits cellular MASTL activity in MCF7 breast cancer cells with an IC50 of 142.7 nM, as measured by reduced phospho-ENSA levels[1].
MKI-2 (100 nM) is selective for MASTL, as it does not inhibit recombinant ROCK1, PKACα, or p70S6K kinases and only slightly inhibits AKT1 at a concentration of 100 nM[1].
MKI-2 (250 nM; 12-24 h) modulates the MASTL-PP2A-c-Myc axis in MCF7, BT549, and MDA-MB-468 breast cancer cells by increasing PP2A activity, reducing phospho-ENSA and total, phospho-c-Myc levels[1].
MKI-2 (250 nM; 24 h) induces mitotic catastrophe in MCF7 breast cancer cells at 250 nM for 24 h, as evidenced by mitotic arrest, altered apoptotic and increased DNA damage marker (γ-H2AX) levels, and increased aberrant nuclear cells[1].
MKI-2 (15.63-1000 nM; 72 h) inhibits the proliferation of MCF7, BT549, MDA-MB-468, and 4T1 breast cancer cells with IC50 values ranging from 56.53 nM to 124.6 nM after 72 h of treatment[1].
MKI-2 (6.25-25 nM) inhibits colony, 3D spheroid, and mammosphere formation of MCF7 breast cancer cells[1].
MKI-2 (250 nM; 24 h) inhibits the migration and invasion of BT549 breast cancer cells at 250 nM for 24 h[1].
MKI-2 (250 nM-2 μM; 12-48 h) reduces the percentage of GVBD and has no significant effects on mouse oocytes viability[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MCF7, BT549, and MDA-MB-468 breast cancer cells
-
Concentration:250 nM
-
Incubation Time:12 h
-
Result:Reduced levels of phospho-ENSA and phospho-c-Myc (Ser62), and decreased total c-Myc protein levels in treated breast cancer cells.
-
Cell Line:MCF7, BT549, MDA-MB-468, and 4T1 breast cancer cells
-
Concentration:15.63-1000 nM
-
Incubation Time:72 h
-
Result:Inhibited proliferation of all tested breast cancer cell lines with IC50 values of 124.6 nM (MCF7), 58.65 nM (BT549), 56.53 nM (4T1), and 94.22 nM (MDA-MB-468).
Chemical Information
-
CAS. Nr. 438204-56-9
-
Molecular Weight 381.43
-
Formel C22H19N7
-
SMILES
N#CCC1=CC=C(NC2=NC(NC3=NNC(C4CC4)=C3)=C5C=CC=CC5=N2)C=C1
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Protokoll
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Cell migration
Cell migration is a method that plays an important role in wound healing, cell differentiation, embryonic development, etc.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Genotoxicity/Mutagenicity Study
The bacterial reverse mutation assay detects point mutations that restore amino-acid prototrophy in auxotrophic Salmonella typhimurium or Escherichia coli tester strains; after exposure to a test article, mutagenic activity is read out as an increased number of revertant colonies on minimal agar compared with the vehicle control. The assay uses tester strains with different mutation targets so that base-substitution and frameshift mutagens can be detected, and testing is performed with and without exogenous mammalian metabolic activation because some chemicals require biotransformation to become mutagenic.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)